您要查找的是不是:
- We got 10 phage clones which could bind with wild-type and mutant Bcr/Abl tyrosine kinase domain. (2)用菌体呈现随机7肽库对构建表达的激酶域蛋白进行了生物淘筛,得到了10个与两种类型激酶域均能结合的共用型噬菌体克隆。
- Production, expression and purification of Bcr-Abl tyrosine kinase domain and its mutants Bcr-Abl酪氨酸蛋白激酶域及其突变体的构建和表达
- Prokaryotic Expression of the Intracellular Tyrosine Kinase Domain of Human Epidermal Growth Factor Receptor 人表皮生长因子受体胞内酪氨酸激酶结构域原核表达
- Tyrosine kinase domain 酪氨酸激酶编码区
- The name is soluble f-m-s-like tyrosine kinase one? 这种蛋白质叫做可溶解fms样酪氨酸激酶一,
- Ligand binds to the extracellular domain of its receptor, causing the activation of the tyrosine kinase domain. Client really wanted to push the idea of activation occuring. 配体正在和受体的膜外的结构域结合,引起了酪氨酸激酶的活化。
- Is PDGF tyrosine kinase inhibitor effective in pancreatic cancer? PDGF受体酪氨酸激酶抑制剂在胰腺癌中是否有作用?
- Objective To construct the antisense nucleic acid eukaryotic expressing vector of the cDNA sequence encoding the transmembrane domain of receptor tyrosine kinase RON (RON-RTK) gene (RONm). 目的构建RON基因跨膜区段(RONm)的反义核酸真核表达载体。
- BACKGROUND & OBJECTIVE: Recent studies showed that somatic mutations in epidermal growth factor receptor (EGFR) tyrosine kinase (TK) domain are assoc iated with sensitivity of non-small cell lung cancer(NSCLC) to TK inhibitor gefi tinib. 背景与目的:最近的研究结果表明,表皮生长因子受体(epidermalgrowthfactorreceptor,EGFR)基因酪氨酸激酶域的体细胞突变与非小细胞肺癌(non鄄smallcelllungcancer,NSCLC)患者对酪氨酸激酶抑制剂吉非替尼的敏感性密切相关。
- The inhibitor of VEGF receptor tyrosine kinase was introduced in detail. 详细介绍了VEGF受体酪氨酸激酶抑制剂的研究进展。
- Sunitinb is a novel multitargeted receptor tyrosine kinase inhibitor. 苏尼替尼是一种新型的多靶点酪氨酸激酶抑制剂。
- The ABL gene encodes a tyrosine kinase whose activity is tightly regulated. ABL基因编码一种活性受到严格调控的酪氨酸激酶。
- Novel Oncogene with Kinase-domain(NOK) is a novel tumor-related gene,coding receptor like protein with a kinase domain. 是一个新的肿瘤相关基因,其结构上与受体蛋白相似,具有一个蛋白激酶结构域。
- FGFR3, a member of polypeptide growth factor family, is a tyrosine kinase receptor. FGFR3是这一多肽类生长因子的家族成员之一,它是一种酪氨酸激酶受体。
- The members of this family lack the conserved catalytic lysine in subdomain II of kinase domain that is crucial for binding to ATP. 该激酶家族成员在通常保守的位于激酶区域第二亚区的赖氨酸位点,赖氨酸被半胱氨酸所替代,但激酶的生物活性没有发生变化。
- Recently, titin has been linked to signal transduction through its kinase domain, which has been proposed to sense mechanical load. 肌小节的激酶区域曾被认为仅仅感受机械负荷,进来发现其与肌小节的信号转导有关。
- The progress in tyrosine kinase inhibitor has been reviewed, including the chemical structures and the pharmacophore models. 本文综述了近年来酪氨酸激酶抑制剂的研究进展,包括抑制剂的结构和与激酶作用的药效团模型。
- Conclusion: The gene of Bcr/Abl kinase domain and its mutants could be cloned and expressed with high pureness in inclusion bodies. 结论: (1)本研究成功扩增了Bcr/Abl蛋白激酶域及其突变体基因,并顺利表达,最终获得高纯度的目的蛋白;
- Isoflavone. Inhibitor of EGFR tyrosine kinase, blocking phosphatidylinositol turnover. 异黄酮类。抑制EGFR酪氨酸激酶。阻断磷脂酰肌糖的翻转。
- STI571 could induce leukemia cells of ANLL into terminal differentiation by inhibiting c-kit tyrosine kinase. STI571对急性非淋巴细胞白血病原代细胞有诱导向同系终末分化的作用,对c-kit酪氨酸激酶有明显的抑制作用,且与药物浓度相关。